productio n of prostate-specific antigen (psa) by a breast cancer cell line, sk-br-3
Authors
abstract
psa is a 33-kda serine protease that is produced predominantly by prostate epithelium. however, it has been shown that about 30-40% of female breast tumors produce psa and its production is associated with the presence of estrogen and progesterone receptors. we have now developed a new tissue culture system to study psa production in breast cancer and its association with prognostic factors such as progesterone receptor and c-erbb-2. for this purpose we investigated the ability of psa production in five different cell lines, including two breast cancer cell lines, sk-br-3 and mda-mb-453. the psa in tissue culture supernatant and cytoplasm of the sk-br-3 cell line was detected by western blotting and immunoperoxidase, respectively. furthermore, we found lower expression of c-erbb-2 in sk-br-3 than non-psa producer breast cancer cell line, mda-mb- 453. progesterone receptor was expressed by both psa-positive and -negative cell lines and only the intensity of staining and the number of positive cells in skbr- 3 population was higher than mda-mb-453. according to our findings psa can be considered as a good prognostic factor in breast cancer and we suggest that these two cell lines are a good in vitro model to study the relationship of different breast cancer prognostic factors and their regulations. keywords: psa, c-erbb-2, progesterone receptor, breast cancer, sk-br-3.
similar resources
PRODUCTIO N OF PROSTATE-SPECIFIC ANTIGEN (PSA) BY A BREAST CANCER CELL LINE, SK-Br-3
PSA is a 33-KDa serine protease that is produced predominantly by prostate epithelium. However, it has been shown that about 30-40% of female breast tumors produce PSA and its production is associated with the presence of estrogen and progesterone receptors. We have now developed a new tissue culture system to study PSA production in breast cancer and its association with prognostic factors...
full textAnti-cancer effects of the combined treatment of trastuzumab and decoy oligodeoxynucleotides to target STAT3 transcription factor on SK-BR-3 breast cancer cell line
Introduction: Breast cancer is the most common malignancy in the female population and is the leading cause of death. Surgery, chemotherapy, radiotherapy, and monoclonal antibody (trastuzumab) therapy are common and standard treatments for this cancer. However, there are significant limitations in the treatment of this disease by using regular methods. Given the role of transcription factors (T...
full textProstate-Specific Antigen (PSA) Test
• Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland. The PSA test measures the level of PSA in the blood (see Question 1). • The U.S. Food and Drug Administration (FDA) has approved the use of the PSA test along with a digital rectal exam to help detect prostate cancer in men age 50 and older. The FDA has also approved the PSA test to monitor patients with a h...
full textCan Prostate Specific Antigen Be Used as New Biomarker for Early Diagnosis of Breast Cancer?
Introduction: As a glycoprotein, Plasma Prostate-Specific Antigen (PSA) is mainly produced by prostate epithelial cells and is used as a major diagnostic tool for prostate cancer. A group of researchers relate the elevated number of estrogen receptors in breast cancer samples to the over-production of PSA in this type of cancer. Therefore, the present study aimed to determine the participants' ...
full textRegulation of Prostate Specific Antigen (PSA) by Activin A in Prostate Cancer LNCaP Cells
Activins are multifunctional growth and differentiation factors, and stimulate follicle-stimulating hormone (FSH)-β gene expression and FSH secretion by the pituitary gonadotropes. Follistatins bind activin, resulting in the neutralization of activin bioactivity. Activin / follistatin system is present in the prostate tissue. Prostate specific antigen (PSA) plays an important role in male repro...
full textEngineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
Background: Recently, modification of T cells with chimeric antigen receptor (CAR) has been an attractive approach for adoptive immunotherapy of cancers. Typically, CARs contain a single-chain variable domain fragment (scFv). Most often, scfvs are derived from a monoclonal antibody of murine origin and may be a trigger for host immune system that leads to the T-cell clearance. Nanobody is a spe...
full textMy Resources
Save resource for easier access later
Journal title:
medical journal of islamic republic of iranجلد ۱۶، شماره ۱، صفحات ۴۱-۴۶
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023